MLICM
XERS icon

Metropolitan Life Insurance Company (MetLife)’s Xeris Biopharma Holdings XERS Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,068
Closed -$8.99K – 2134
2024
Q1 		$8.99K Sell
4,068
-6
-0.1% -$16 ﹤0.01% 2166
2023
Q4 		$9.57K Buy
+4,074
New +$7.52K ﹤0.01% 2194
2023
Q2 		– Sell
-7,329
Closed -$11.9K – 2525
2023
Q1 		$11.9K Sell
7,329
-1,211
-14% -$1.52K ﹤0.01% 2092
2022
Q4 		$11.4K Buy
8,540
+6,740
+374% +$9.51K ﹤0.01% 2246
2022
Q3 		$2.81K Sell
1,800
-6,423
-78% -$10.6K ﹤0.01% 2308
2022
Q2 		$12.7K Buy
+8,223
New +$17.4K ﹤0.01% 2254
2020
Q4 		– Sell
-15,523
Closed -$92.1K – 2578
2020
Q3 		$92.1K Buy
+15,523
New +$62.1K ﹤0.01% 2263
2019
Q4 		– Sell
-10,158
Closed -$99.9K – 2562
2019
Q3 		$99.9K Buy
10,158
+7,943
+359% +$89.3K ﹤0.01% 2304
2019
Q2 		$25.3K Buy
+2,215
New +$23.3K ﹤0.01% 2577

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s XERS Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Xeris Biopharma Holdings (XERS) in Q2 2024, closing a stake of 4,068 shares — an estimated $8.99K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in XERS in Q2 2019 and held it in 9 quarters. The position peaked at $99.9K in Q3 2019. 134 funds tracked by Wall St. Rank hold XERS as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Xeris Biopharma Holdings position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 4,068 Xeris Biopharma Holdings shares in Q2 2024, an estimated $8.99K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Xeris Biopharma Holdings in Q2 2019 and held it in 9 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Xeris Biopharma Holdings position peaked at $99.9K in Q3 2019.
  • 134 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.